EORTC QOL researchers receive awards to present at the European Cancer Congress 2013 and ISOQOL 2013

July 04, 2013

The Executive Scientific Committee of the 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress 2013 has awarded Efstathios Zikos and Divine Ediebah of the EORTC Quality of Life Department Fellowship Grants to attend the European Cancer Congress 2013 which will be held in Amsterdam from 27 September to 1 October 2013.

Divine will present a poster, "Patient-proxy agreement of health-related quality of life (HRQOL) measurements in low-grade glioma patients" (Abstract Id: E17-2609), during the "Symptom Science" poster session scheduled on Monday, September 30, 2013 from 09:30 to 12:00 o'clock. In this same session Efstathios will present, "Health-related quality of life in small-cell lung cancer: A systematic review on reporting of methodological and clinical issues in randomized controlled trials" (Abstract Id: E17-2527). Efstathios' abstract will also be discussed in a Poster Discussion Session.

The two quality of life researchers will also present research results at the 20th Annual Conference of the International Society for Quality of Life Researchers (ISOQOL) to be held 9-12 October 2013 in Miami, Florida. Efstathios Zikos will present "A Review of Health-Related Quality of Life Assessment in

EORTC Cancer Clinical Trials" (Presentation Number: 1090), and Divine Ediebah will present "Patient-proxy agreement of health-related quality of life (HRQOL) measurements in low-grade glioma patients" (Presentation Number: 1093). For his presentation at ISOQOL, Divine was chosen by the Scholarship Selection Committee to receive one of this year's Developing Country Scholarships.

These research projects were supported by the EORTC Charitable Trust, La Fondation Contre le Cancer, and Patient Reported Outcome and Behavioral Evidence (PROBE).

Divine E. Ediebah has been a Fellow Biostatistician in the Quality of Life Department at EORTC Headquarters since March 2011. He is involved biostatistical analyses on clinical trials data in the Patient Reported Outcome and Behavioral Evidence (PROBE) projects and works in collaboration with the various EORTC disease oriented groups. He holds Masters Degrees in Applied Statistics and Biostatistics from Hasselt University and worked previously as a consultant in Biostatistics with GlaxoSmithKline Biological's 4Clinics for clinical studies for Flu, Malaria and Herpes Zoster vaccines. His research interests include methods in the analyses of Quality of Life data from clinical trials, longitudinal data, survival data, multivariate data and categorical data analysis and joint modeling. He is currently pursuing his PhD at the VU Medical Center of Amsterdam (joint modeling of HRQOL outcome and other biomarkers such as overall survival, progression-free survival, MMSE, genetic biomarkers, etc).

Efstathios Zikos is Quality of Life Research Manager/Scientific Coordinator in the EORTC Headquarters Quality of Life Department since March 2011. He leads the daily supervision of the PROBE team and is responsible for major research studies from conception to publication and the coordination of the advisory board of PROBE. He received his BSc in Psychology from Anglia Ruskin University, Cambridge, his MSc in Social and Organizational Psychology from Leiden University, and his interdisciplinary MA in Society, Science and Technology from Maastricht University. He completed his specialty in Management and Economics of Innovation, at the Autonomous University of Madrid, and his practical training in clinical psychopathology and neuropsychological assessment at the 1st Psychiatric Department of Athens University Medical School. He attained his certification as a Licensed Psychologist from the Greek Authorities and has worked as a Science and Technology Consultant and volunteer psychologist to vulnerable groups of patients, refugees and children for the Red Cross, the Médecins sans Frontières and the Arc of the World. He is currently pursuing his PhD in the Academic Medical Center of the University of Amsterdam (Methodological challenges in HRQOL research and analysis of patient-reported outcomes data in EORTC cancer clinical trials).
-end-


European Organisation for Research and Treatment of Cancer

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.